Cargando…

Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients

BACKGROUND: Anti-Androgen Receptor (AR) therapy holds promise for a subset of AR expressing triple-negative breast cancer (TNBC) patients. However, current AR assays are suboptimal in detecting the dynamic range of AR expression, contributing to its controversial role in TNBC disease prognosis. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Govindan, Sindhu, Siraganahalli Eswaraiah, Mallikarjuna, Basavaraj, Chetana, Adinarayan, Manjula, Sankaran, Satish, Bakre, Manjiri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419184/ https://www.ncbi.nlm.nih.gov/pubmed/32778063 http://dx.doi.org/10.1186/s12885-020-07218-0

Ejemplares similares

A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort
por: Gunda, Aparna, et al.
Publicado: (2022)

The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment
por: Eshwaraiah, Mallikarjuna Siraganahalli, et al.
Publicado: (2023)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario
por: Sankaran, Satish, et al.
Publicado: (2019)

Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor–Positive Breast Cancer
por: Ramkumar, Charusheila, et al.
Publicado: (2018)

A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast
por: Gunda, Aparna, et al.
Publicado: (2022)

CLINICOPATHOLOGICAL EVALUATION OF NONMELANOMA SKIN CANCER
por: Adinarayan, Manjula, et al.
Publicado: (2011)

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin
por: Chandra Doval, Dinesh, et al.
Publicado: (2021)

Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients
por: Attuluri, Arun Kumar, et al.
Publicado: (2019)

Clinical validation of an immunohistochemistry‐based CanAssist‐Breast test for distant recurrence prediction in hormone receptor‐positive breast cancer patients
por: Bakre, Manjiri M., et al.
Publicado: (2019)

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
por: Brumec, Maša, et al.
Publicado: (2021)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2017)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
por: Mina, Alain, et al.
Publicado: (2017)

ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer
por: Liu, Yan, et al.
Publicado: (2015)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
por: Thakkar, A., et al.
Publicado: (2016)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Speers, Corey, et al.
Publicado: (2017)

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
por: Zhang, Xi, et al.
Publicado: (2023)

Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options
por: Gasparini, Pierluigi, et al.
Publicado: (2014)

Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
por: Wang, Changjun, et al.
Publicado: (2016)

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features
por: Astvatsaturyan, Kristine, et al.
Publicado: (2018)

Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer
por: Lee, Reeree, et al.
Publicado: (2022)

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria
por: Haruna, Muibat, et al.
Publicado: (2022)

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?
por: Dubrava, Alex L, et al.
Publicado: (2023)

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer: pCDK2 in luminal androgen receptor TNBC
por: Jin, Zining, et al.
Publicado: (2022)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
por: Pistelli, Mirco, et al.
Publicado: (2014)

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor
por: Doberstein, Kai, et al.
Publicado: (2014)

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
por: Bhattarai, Shristi, et al.
Publicado: (2019)

Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer
por: Hu, Xiao-Qing, et al.
Publicado: (2017)

Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2019)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin
por: Kwilas, Anna R., et al.
Publicado: (2016)

Update on triple-negative breast cancer: prognosis and management strategies
por: Brouckaert, Olivier, et al.
Publicado: (2012)

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis
por: Zhang, Li, et al.
Publicado: (2015)

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer
por: Hamilton, Nalo, et al.
Publicado: (2017)

Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer
por: Roseweir, Antonia K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i48f4kntsjok347p3a8579ondt